Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (321-330 of 404) with videos related to

Pageof 41
Sort By:
The Lancet. Gastroenterology & Hepatology|April 27, 2017
Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort studyJason Grebely, Francois M J Lamoury, Behzad Hajarizadeh, et al.
Drug and Alcohol Review|December 5, 2025
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on OpioidsM J Stowe, Anna Conway, Frederick L Altice, et al.
International Journal of Epidemiology|February 20, 2026
New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort studyJiahui Qian, Sandrine Stepien, Allen Cheng, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
The Lancet. Global Health|March 30, 2023
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic reviewLouisa Degenhardt, Paige Webb, Samantha Colledge-Frisby, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 CollaborativeAryan Esmaeili, Ali Mirzazadeh, Meghan D Morris, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Health Science Reports|August 24, 2022
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohortSofia R Bartlett, Andrey Verich, Joanne Carson, et al.
Pageof 41

Showing results (321-330 of 404) with videos related to

Sort By:
Pageof 41
The Lancet. Gastroenterology & Hepatology|April 27, 2017
Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort studyJason Grebely, Francois M J Lamoury, Behzad Hajarizadeh, et al.
Drug and Alcohol Review|December 5, 2025
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on OpioidsM J Stowe, Anna Conway, Frederick L Altice, et al.
International Journal of Epidemiology|February 20, 2026
New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort studyJiahui Qian, Sandrine Stepien, Allen Cheng, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
The Lancet. Global Health|March 30, 2023
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic reviewLouisa Degenhardt, Paige Webb, Samantha Colledge-Frisby, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 CollaborativeAryan Esmaeili, Ali Mirzazadeh, Meghan D Morris, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Health Science Reports|August 24, 2022
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohortSofia R Bartlett, Andrey Verich, Joanne Carson, et al.
Pageof 41